Drugs / AV0328
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02853617 | Mar 2017 → Apr 2018 | — | Alopexx Vaccine, LLC | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-09-10 | Alopexx Oncology, LLC | Alopexx Announces Collaboration with Bharat Biotech for the Development and Commercialization of Broad-Spectrum Anti-Microbial Vaccine AV0328 alopexx.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AV0328 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02853617 ↗ |
| Modality | Vaccine | “novel vaccine candidate” NCT02853617 ↗ |
| Route | Intramuscular | “intramuscularly administered AV0328” NCT02853617 ↗ |